Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2013

Lian Bin, Si Lu, Cui Chuanliang, Chi Zhihong, Sheng Xinan, Mao Lili, Li Siming, Kong Yan, Tang Bixia, Guo Jun

Abstract excerpt

PURPOSE: Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal melanoma has not been established. We conducted a randomized phase II clinical trial in patients with resected mucosal melanoma to compare the efficacy and safety of high-dose IFN-α2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy. EXPERIMENTAL DESIGN: Patients with mucosal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Dacarbazine

Share to Interferon-alpha

Share to Mucous Membrane

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Source

Identifiers

PMID: 23833309
DOI: 10.1158/1078-0432.CCR-13-0739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.PMID 23833309Read ↗

Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.Semantic proximity Read ↗

Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.Semantic proximity Read ↗

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read ↗

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of MelanomaSemantic proximity Read ↗

Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.Semantic proximity Read ↗

Gene Mutation Characteristics and Clinical Prognosis of Head and Neck Mucosal MelanomaSemantic proximity Read ↗

Primary Gastric Melanoma – Is an Aggressive Strategy Worthwhile?Semantic proximity Read ↗

Optimal strategy in managing advanced melanoma.Semantic proximity Read ↗

Mucosal melanoma of the head and neck: a systematic review of the literature.Semantic proximity Read ↗

A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaSemantic proximity Read ↗

Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.Semantic proximity Read ↗

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.